Analysis
Three IPOs priced in the four days from October 27 to October 30, 2026 raised a combined $613.5 million, with fintech company OPay's $304 million NYSE debut the largest of the group -- a week Pulse's own tracking shows splitting between a fintech rebound story and a cautious biotech recovery, even as Anthropic's far larger IPO looms with a compute-commitment question still unresolved.
This week's IPO scorecard
- OPay -- priced at $19.00 per ADS, the low end of its range, for about $304 million in gross proceeds on 16 million ADSs; the Nigeria-born fintech has more than 50 million monthly active users as of July 2026 and was last valued at $2 billion in its 2021 Series C, per Pulse's coverage.
- Bambusa Therapeutics -- priced an upsized offering of 10.56 million shares at $16.00, raising $168.9 million, implying a roughly $815.7 million market cap at pricing, after $136.1 million in pre-IPO private financings, per Pulse.
- Aspen Neuroscience -- priced 9.375 million shares at $15.00 for about $140.6 million, after raising more than $340 million privately, including a $115 million Series C in November 2025, per Pulse.
A fintech rebound and a cautious biotech one
OPay's pricing at the low end of its range, rather than above it, suggests investor appetite for emerging-market fintech is real but not exuberant -- a far cry from 2021, when the company was valued at $2 billion in private markets. Bambusa and Aspen Neuroscience priced the same morning, part of what BioSpace called a "cautiously optimistic" biotech IPO rebound; both priced within their ranges rather than upsizing on pure demand, and both still needed meaningful private capital before going public at all. That pattern -- pricing in range, not above it, and leaning on prior private rounds to get to the start line -- is the throughline across all three deals this week, regardless of sector.
“Anthropic's S-1 locks in $417 billion to $567 billion in compute commitments years before matching revenue exists.”
The number that dwarfs this week's total
$613.5 million is a rounding error next to what's coming. Anthropic's S-1 locks in $417 billion to $567 billion in compute commitments years before matching revenue exists.
If even a sliver of the capital-markets attention that three mid-size IPOs absorbed this week gets redirected toward underwriting Anthropic's roadshow, this week's total looks like a warm-up act, not a comparable data point. The risk for smaller issuers queued behind Anthropic is that its roadshow could crowd out investor and underwriter attention for weeks, pushing other 2026 listings to reschedule around it.
What to watch next
Watch whether more biotech issuers follow Bambusa and Aspen Neuroscience's same-day pricing pattern -- a sign underwriters are bundling smaller, similar-sized biotech offerings to manage scarce demand -- and whether OPay's low-end pricing becomes the template other emerging-market fintechs use to get deals done even when they can't command their top ask. The next test comes from the SEC's own pipeline: several more S-1 filings and 424B4 pricings landed this same week, and how underwriters space those out around Anthropic's roadshow will say more about 2026's IPO market than any single week's total.